Acoustic neuroma medical therapy: Difference between revisions
Line 88: | Line 88: | ||
====Proton beam therapy==== | ====Proton beam therapy==== | ||
*The use of [[proton]] beam therapy permits the delivery of high doses of radiotherapy to the target volume while limiting the dose received by surrounding tissues. It provides maximum local tumor control with minimum [[cranial nerve]] injuries. | *The use of [[proton]] beam therapy permits the delivery of high doses of radiotherapy to the target volume while limiting the dose received by surrounding tissues. It provides maximum local tumor control with minimum [[cranial nerve]] injuries. | ||
==References== | ==References== |
Revision as of 21:12, 15 January 2019
Acoustic neuroma Microchapters | |
Diagnosis | |
---|---|
Treatment | |
Case Studies | |
Acoustic neuroma medical therapy On the Web | |
American Roentgen Ray Society Images of Acoustic neuroma medical therapy | |
Risk calculators and risk factors for Acoustic neuroma medical therapy | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2] Mohsen Basiri M.D.
Overview
The mainstay of therapy for acoustic neuroma is surgery and radiation therapy. Since acoustic neuroma tends to be slow-growing and is benign tumor, careful observation with follow-up MRI scans every 6 to 12 months may be appropriate for elderly patients or patients with small tumors, or among patients with significant medical conditions and patients who refuse treatment.
Medical Therapy
The mainstay of therapy for acoustic neuroma is surgery and radiation therapy. Since acoustic neuroma tends to be slow-growing and is benign tumor, careful observation with follow-up MRI scans every 6 to 12 months may be appropriate among following groups of patients:[1][2]
- Patients with a tumor in their only hearing or better hearing ear
- When the tumor is of a size that hearing preservation with treatment would be unlikely
- Elderly patients
- Small tumors in older individuals that do not grow
- Patients with small tumors with good hearing
- Patients with medical conditions that increase the risk of surgery
- Patients who refuse treatment
- Patients with a tumor on the side of an only hearing ear or only seeing eye
Observation
The strategies for patient observation include:
- Assessment of facial nerve function, hearing, tinnitus and ataxia.
- An MRI is performed every 6 months or yearly depending on the rate of tumor growth.
- The average growth rate of tumor is 1.15 to 2.4 mm per year. If the tumor grows or causes serious symptoms, treatment is suggested. If the scans show the tumor is growing or If the tumor causes progressive symptoms or other difficulties, considering surgical intervention is mandatory. [3]
Radiation Therapy
Another treatment option for an acoustic neuroma is radiation. Radiation therapy approaches that have been used in patients with acoustic neuroma include:
- Stereotactic radiosurgery
- Stereotactic radiotherapy
- Proton beam therapy
Stereotactic radiosurgery
Stereotactic radiosurgery (SRS), is a treatment option for patients with tumors smaller than 3 centimeter or for enlarging tumors in patients with significant medical conditions and are not candidates for surgery. It delivers multiple precisely-targeted radiation convergent beams to minimize injury to adjacent structures. This can be accomplished with either the gamma knife or a linear accelerator.[4][5]
Stereotactic radiotherapy
Stereotactic radiotherapy (SRT), fractionated stereotactic radiotherapy, delivers smaller doses of radiation over a period of time, requiring the patient to return to the treatment location on a daily basis, from 3 to 30 times, generally over several weeks. Each visit lasts a few minutes and most patients are free to go about their daily business before and after each treatment session. Early data indicates that SRT may result in better hearing preservation when compared to single-session SRS.[6]
Proton beam therapy
- The use of proton beam therapy permits the delivery of high doses of radiotherapy to the target volume while limiting the dose received by surrounding tissues. It provides maximum local tumor control with minimum cranial nerve injuries.
References
- ↑ Wissame El Bakkouri, Romain E. Kania, Jean-Pierre Guichard, Guillaume Lot, Philippe Herman & Patrice Tran Ba Huy (2009). "Conservative management of 386 cases of unilateral vestibular schwannoma: tumor growth and consequences for treatment". Journal of neurosurgery. 110 (4): 662–669. doi:10.3171/2007.5.16836. PMID 19099381. Unknown parameter
|month=
ignored (help) - ↑ Eric E. Smouha, Michael Yoo, Kristi Mohr & Raphael P. Davis (2005). "Conservative management of acoustic neuroma: a meta-analysis and proposed treatment algorithm". The Laryngoscope. 115 (3): 450–454. doi:10.1097/01.mlg.0000175681.52517.cf. PMID 15744156. Unknown parameter
|month=
ignored (help) - ↑ Wissame el Bakkouri, M.D., romain e. kania, M.D., Ph.D., Jean-Pierre Guichard, M.D., Guillaume lot, M.D., Philippe herman, M.D., Ph.D., and Patrice tran Ba huy, M.D. (2007). "Conservative management of 386 cases of unilateral vestibular schwannoma: tumor growth and consequences for treatment". J Neurosurg. 11: 662.
- ↑ Marianna Karpinos, Bin S. Teh, Otto Zeck, L. Steven Carpenter, Chris Phan, Wei-Yuan Mai, Hsin H. Lu, J. Kam Chiu, E. Brian Butler, William B. Gormley & Shiao Y. Woo (2002). "Treatment of acoustic neuroma: stereotactic radiosurgery vs. microsurgery". International journal of radiation oncology, biology, physics. 54 (5): 1410–1421. PMID 12459364. Unknown parameter
|month=
ignored (help) - ↑ Joseph C. T. Chen & Michael R. Girvigian (2005). "Stereotactic radiosurgery: instrumentation and theoretical aspects-part 1". The Permanente journal. 9 (4): 23–26. PMID 22811641. Unknown parameter
|month=
ignored (help) - ↑ Marianna Karpinos, Bin S. Teh, Otto Zeck, L. Steven Carpenter, Chris Phan, Wei-Yuan Mai, Hsin H. Lu, J. Kam Chiu, E. Brian Butler, William B. Gormley & Shiao Y. Woo (2002). "Treatment of acoustic neuroma: stereotactic radiosurgery vs. microsurgery". International journal of radiation oncology, biology, physics. 54 (5): 1410–1421. PMID 12459364. Unknown parameter
|month=
ignored (help)